What Will Happen to Atara Biotherapeutics Inc (NASDAQ:ATRA) Next? The Stock Has Decline in Shorts

November 10, 2018 - By Margaret Downey

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Logo

Investors sentiment decreased to 1.89 in 2018 Q2. Its down 1.97, from 3.86 in 2018Q1. It worsened, as 11 investors sold Atara Biotherapeutics, Inc. shares while 26 reduced holdings. 19 funds opened positions while 51 raised stakes. 44.51 million shares or 46.45% less from 83.11 million shares in 2018Q1 were reported.
Goldman Sachs owns 422,103 shares for 0% of their portfolio. Manufacturers Life Insurance The accumulated 0% or 29,969 shares. Susquehanna Int Group Inc Limited Liability Partnership has 48,031 shares for 0% of their portfolio. Polar Capital Llp holds 0.02% of its portfolio in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) for 100,000 shares. Putnam Invs Limited Liability Co holds 0.02% or 296,259 shares. Barclays Public Ltd holds 0% or 2,978 shares in its portfolio. State Board Of Administration Of Florida Retirement System reported 17,296 shares. Meeder Asset Mngmt has invested 0% in Atara Biotherapeutics, Inc. (NASDAQ:ATRA). Bancshares Of Ny Mellon has 0% invested in Atara Biotherapeutics, Inc. (NASDAQ:ATRA). Jefferies Group Inc Ltd holds 0.01% or 25,923 shares in its portfolio. Credit Suisse Ag accumulated 37,592 shares or 0% of the stock. Ubs Asset Mngmt Americas Inc stated it has 232,656 shares. Parallax Volatility Advisers Limited Partnership has 0% invested in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) for 311 shares. State Of Wisconsin Invest Board invested in 0% or 41,400 shares. Amer Grp has 0% invested in Atara Biotherapeutics, Inc. (NASDAQ:ATRA).

Since May 14, 2018, it had 1 buying transaction, and 17 selling transactions for $8.28 million activity. Ciechanover Isaac E. sold 7,800 shares worth $306,923. Newell Joe had sold 1,500 shares worth $59,178 on Tuesday, September 4. Haqq Christopher sold $29,094 worth of stock or 775 shares. Shares for $735,357 were sold by Porter Derrell on Tuesday, May 15. Clark Mitchall G. sold 25,860 shares worth $1.29 million. Fust Matthew K had sold 12,286 shares worth $535,301 on Monday, May 14.

The stock of Atara Biotherapeutics Inc (NASDAQ:ATRA) registered a decrease of 3.25% in short interest. ATRA’s total short interest was 6.19M shares in November as published by FINRA. Its down 3.25% from 6.39 million shares, reported previously. With 515,100 shares average volume, it will take short sellers 12 days to cover their ATRA’s short positions. The short interest to Atara Biotherapeutics Inc’s float is 21.41%.

The stock decreased 4.23% or $1.6 during the last trading session, reaching $36.23. About 706,880 shares traded or 22.39% up from the average. Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has risen 165.68% since November 10, 2017 and is uptrending. It has outperformed by 150.06% the S&P500.

Atara Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for patients with severe and life-threatening diseases in the United States. The company has market cap of $1.64 billion. The Company’s clinical stage T-cell product candidates include ATA129 that focuses on Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus associated post-transplant lymphoproliferative disorder after hematopoietic cell transplant and solid organ transplant; ATA188, which is in Phase I clinical trial for the treatment of multiple sclerosis; ATA520, a Phase I clinical trial product targeting cancers expressing the antigen Wilms tumor 1; and ATA230, which is Phase III clinical trials for refractory cytomegalovirus. It currently has negative earnings. The firm is also developing a next generation of allogeneic T-cell product candidates utilizing a technology to selectively enhance a T-cellÂ’s ability to target specific viral proteins implicated in disease.

Another recent and important Atara Biotherapeutics, Inc. (NASDAQ:ATRA) news was published by Streetinsider.com which published an article titled: “ATARA Biotherapeutics (ATRA) Announces Presentations at ASH” on November 01, 2018.

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: